GLP-1 therapies helped drive a 79% year-over-year increase in strategic pharmaceutical M&A deal value through mid-November 2025, as drugmakers ramped up efforts to meet surging demand and expand their metabolic portfolios. According to Bain & Co.’s Global M&A Report 2026, the spike in activity reflects a shift in strategy: Acquirers are no longer focused solely on individual products, but are instead building full-platform control. That includes securing proprietary delivery technologies, expanding manufacturing capacity and investing in next-generation mechanisms.
Read the full article: GLP-1 Momentum Drives 79% Pharma M&A Surge //
Source: https://www.beckershospitalreview.com/glp-1s/glp-1-momentum-drives-79-pharma-ma-surge/